Rosiglitazon udviste moderat inhibition af CYP2C8 (IC50 8 μM) og lav inhibition af CYP2C9 (IC50 50 μM) in vitro (se afsnit 4. 5).
Rosiglitazone showed moderate inhibition of CYP2C8 (IC50 18 µM) and low inhibition of CYP2C9 (IC50 50 µM) in vitro (see section 4.5).